Top Page
China Health Group
(0673)
China Health Group (0673) vs. iShares MSCI Hong Kong ETF (EWH)
China Health Group Business Overview & Revenue Model
China Health Group Financial Statement Overview
| Breakdown | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 38.94M | 59.93M | 76.41M | 107.03M | 87.89M |
| Gross Profit | 9.23M | 13.64M | 27.19M | 28.69M | 25.99M |
| EBITDA | -63.71M | -37.42M | -33.04M | -4.38M | -1.47M |
| Net Income | -67.79M | -40.19M | -42.05M | -12.21M | -7.74M |
Balance Sheet | |||||
| Total Assets | 147.35M | 192.32M | 221.19M | 225.96M | 217.82M |
| Cash, Cash Equivalents and Short-Term Investments | 1.05M | 4.01M | 11.48M | 8.54M | 4.59M |
| Total Debt | 6.50M | 5.66M | 6.04M | 18.47M | 5.36M |
| Total Liabilities | 147.25M | 132.56M | 127.23M | 140.82M | 117.83M |
| Stockholders Equity | -7.66M | 52.04M | 86.33M | 79.58M | 95.04M |
Cash Flow | |||||
| Free Cash Flow | -8.35M | -7.03M | -9.59M | 31.00M | -10.90M |
| Operating Cash Flow | -6.76M | -6.40M | -8.22M | 31.80M | -9.06M |
| Investing Cash Flow | -1.58M | -301.00K | -5.40M | -35.29M | -1.84M |
| Financing Cash Flow | 8.79M | -1.24M | 27.66M | 12.96M | 2.63M |
China Health Group Technical Analysis
China Health Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$64.66B | 3.78 | 8.74% | 3.75% | -2.68% | -21.45% | |
66 Neutral | HK$1.91B | 20.84 | 5.07% | 3.81% | 0.33% | -44.28% | |
64 Neutral | HK$64.20B | 15.13 | 7.53% | 2.67% | 2.77% | 39.24% | |
60 Neutral | HK$626.40M | 7.99 | 8.12% | 8.03% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | HK$846.15M | -5.63 | -465.55% | ― | -17.39% | -45.76% | |
40 Underperform | HK$450.41M | -0.52 | -69.05% | ― | -43.86% | -217.25% |
China Health Group Corporate Events
China Health Group Limited has completed a share subscription, issuing 48 million new shares at HK$0.53 each under a general mandate, expanding its share capital by about 3.6 percent. The new shares represent roughly 3.46 percent of the enlarged capital base, slightly diluting existing holdings of major shareholders and public investors while introducing a new subscriber.
The transaction will raise net proceeds of about HK$25.27 million, with around 40 percent earmarked for future investments and the remaining 60 percent allocated to general working capital, including staff costs, rent, and supplier payments. The capital injection is expected to strengthen the group’s liquidity position and support ongoing operations and potential investment opportunities, with controlling shareholders retaining majority control despite marginal dilution.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.58 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited has cancelled in full the 40,638,000 share options it granted on 2 February 2026 to 11 grantees, exercising the board’s discretion under its share option scheme after none of the options had been validly exercised. The cancellation means these options are still counted as utilised for the purpose of the scheme’s overall and service provider mandate limits, leaving 7,261,476 shares and 4,789,947 shares, respectively, available for future grants, which could influence how the group structures future equity incentives and capital management.
The board’s move effectively closes this particular round of incentive awards while preserving the remaining capacity under the scheme for potential reallocation in line with future strategic or human capital needs. For shareholders and other stakeholders, the decision signals an adjustment in the company’s approach to option-based remuneration without an immediate dilutive impact from the cancelled grant, although the reserved capacity may still be deployed in subsequent grants.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.58 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited has granted 40,638,000 share options, equivalent to about 3.03% of its issued share capital, to 11 directors and employees under its share option scheme adopted in September 2023. The options, exercisable at HK$0.66 per share with a ten-year term and a one-year vesting period ending on 2 February 2027, are intended as recognition of past contributions and as an incentive for future performance, with no formal performance targets but with a clawback mechanism in cases of misconduct, reflecting the group’s continued use of equity incentives to retain key talent and align staff interests with shareholders while maintaining governance safeguards.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.58 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited has entered into a subscription agreement with an independent Hong Kong investment holding company to issue 48 million new shares under its existing general mandate at HK$0.53 per share. The new shares will represent about 3.58% of the current share capital (3.46% post-issuance), raising approximately HK$25.44 million in gross proceeds and HK$25.27 million in net proceeds, with the shares ranking pari passu with existing equity; completion remains subject to Stock Exchange approval for listing and dealing in the new shares, and the company has cautioned investors that the transaction may or may not proceed, implying moderate dilution for existing shareholders in exchange for fresh capital to support its operations or financial position.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.58 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited has provided an update on measures to address its auditors’ disclaimer of opinion on the company’s ability to continue as a going concern for the year ended 31 March 2025. The company has completed share subscriptions and a rights issue, raising net proceeds of about HK$80.9 million to ease liquidity pressure, is negotiating the renewal of approximately HK$5.4 million in bank borrowings targeted for completion by the end of the first quarter of 2026, and continues to explore additional funding channels as needed. Management has committed to publishing progress updates every three months until the going-concern disclaimer is resolved and has cautioned shareholders and investors to exercise care when trading its securities, underscoring ongoing financial uncertainty despite recent capital-raising efforts.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.78 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited reported its unaudited condensed consolidated interim financial results for the six months ending September 30, 2025. The company experienced a slight increase in revenue to HK$19,610,000 from HK$18,680,000 in the previous year. However, it faced a loss before tax of HK$10,889,000, which is an improvement from the previous year’s loss of HK$17,607,000. The total comprehensive loss for the period was HK$10,648,000, showing a reduction from the previous year’s loss of HK$18,130,000. Despite the losses, the financial results indicate a narrowing of losses, which could suggest potential stabilization or improvement in the company’s financial health.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.
China Health Group Limited has announced a supplemental update to its annual report for the financial year ending March 31, 2025. The update highlights an impairment loss of approximately HK$11.7 million related to expected credit losses on loan and interest receivables. The company has taken legal action to recover a loan from Shuangluan Hospital, with ongoing litigation at the Chengde Court and discussions with the Shuangluan Government for possible repayment plans. The outcome of these actions could significantly impact the company’s financial recovery efforts and its stakeholders.
The most recent analyst rating on (HK:0673) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on China Health Group stock, see the HK:0673 Stock Forecast page.